Promise and pitfalls of animal models of schizophrenia
- PMID: 20544314
- PMCID: PMC2895894
- DOI: 10.1007/s11920-010-0122-x
Promise and pitfalls of animal models of schizophrenia
Abstract
Animal models are indispensible tools for advancing understanding of the cause of any given disease and developing new treatments. Developing animal models for schizophrenia presents formidable challenges owing to the distinctively human nature of the symptoms that define it and the thus-far-obscured underlying biological mechanisms. Nevertheless, progress has been and continues to be made in this important field of endeavor. This article discusses the challenges facing investigators who seek to develop and use animal models for translational research in schizophrenia and the responses that have emerged to those challenges, as well as the likely pathways that will lead to future progress.
Similar articles
-
Developing zebrafish experimental animal models relevant to schizophrenia.Neurosci Biobehav Rev. 2019 Oct;105:126-133. doi: 10.1016/j.neubiorev.2019.07.017. Epub 2019 Jul 29. Neurosci Biobehav Rev. 2019. PMID: 31369798 Review.
-
Reconsideration of animal models of schizophrenia and other psychiatric disorders with evolutionary perspective.Med Hypotheses. 2013 Dec;81(6):1120-6. doi: 10.1016/j.mehy.2013.10.017. Epub 2013 Oct 21. Med Hypotheses. 2013. PMID: 24199948
-
Behavioral and molecular biomarkers in translational animal models for neuropsychiatric disorders.Int Rev Neurobiol. 2011;101:203-38. doi: 10.1016/B978-0-12-387718-5.00008-0. Int Rev Neurobiol. 2011. PMID: 22050853 Review.
-
Inducible and conditional transgenic mouse models of schizophrenia.Prog Brain Res. 2009;179:35-47. doi: 10.1016/S0079-6123(09)17905-0. Epub 2009 Nov 20. Prog Brain Res. 2009. PMID: 20302816 Review.
-
Challenges in understanding psychiatric disorders and developing therapeutics: a role for zebrafish.Dis Model Mech. 2015 Jul 1;8(7):647-56. doi: 10.1242/dmm.019620. Dis Model Mech. 2015. PMID: 26092527 Free PMC article. Review.
Cited by
-
Microglia sequelae: brain signature of innate immunity in schizophrenia.Transl Psychiatry. 2022 Nov 28;12(1):493. doi: 10.1038/s41398-022-02197-1. Transl Psychiatry. 2022. PMID: 36443303 Free PMC article. Review.
-
Hypofrontality and Posterior Hyperactivity in Early Schizophrenia: Imaging and Behavior in a Preclinical Model.Biol Psychiatry. 2017 Mar 15;81(6):503-513. doi: 10.1016/j.biopsych.2016.05.019. Epub 2016 May 30. Biol Psychiatry. 2017. PMID: 27450031 Free PMC article.
-
Clinical and Structural Differences in Delusions Across Diagnoses: A Systematic Review.Front Integr Neurosci. 2022 Jan 24;15:726321. doi: 10.3389/fnint.2021.726321. eCollection 2021. Front Integr Neurosci. 2022. PMID: 35140591 Free PMC article.
-
Assessing Reality Testing in Mice Through Dopamine-Dependent Associatively Evoked Processing of Absent Gustatory Stimuli.Schizophr Bull. 2020 Jan 4;46(1):54-67. doi: 10.1093/schbul/sbz043. Schizophr Bull. 2020. PMID: 31150554 Free PMC article.
-
Behavioral Tasks Evaluating Schizophrenia-like Symptoms in Animal Models: A Recent Update.Curr Neuropharmacol. 2021;19(5):641-664. doi: 10.2174/1570159X18666200814175114. Curr Neuropharmacol. 2021. PMID: 32798374 Free PMC article. Review.
References
-
- American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders. 4 (text revision) Washington, DC: American Psychiatric Association; 2000.
-
- Geyer MA, Markou A. The role of preclinical models in the development of psychotropic drugs. In: Davis KL, Charney D, Coyle JT, Nemeroff CB, editors. Neuropsychopharmacology: The Fifth Generation of Progress. Washington, DC: American College of Neuropsychopharmacology; 2002. pp. 445–455.